Kelly-Ann S Schlegel

Title: The Innovative Contributions of Kelly-Ann S Schlegel

Introduction

Kelly-Ann S Schlegel is a prominent inventor based in Fleetwood, PA (US). She has made significant contributions to the field of pharmaceuticals, holding a total of four patents. Her work focuses on developing compounds that target various diseases, showcasing her commitment to advancing medical science.

Latest Patents

One of her latest patents is titled "3-aryl-heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (HDAC6) inhibitors." This invention is directed towards substituted 5-trifluoromethyl oxadiazole compounds, which may be useful in treating cellular proliferative diseases, including cancer and neurodegenerative diseases such as schizophrenia and stroke. Another notable patent is for "Quinoline amide M1 receptor positive allosteric modulators." This invention involves quinoline amide compounds that serve as M1 receptor positive allosteric modulators, useful in treating diseases like Alzheimer's disease, schizophrenia, pain, and sleep disorders.

Career Highlights

Kelly-Ann Schlegel is currently employed at Merck Sharp & Dohme Corporation, where she continues to innovate and contribute to the pharmaceutical industry. Her work has been instrumental in developing new therapeutic options for patients suffering from various conditions.

Collaborations

Throughout her career, Kelly-Ann has collaborated with notable colleagues, including Zhi-Qiang Yang and James C Barrow. These collaborations have further enhanced her research and development efforts in the pharmaceutical field.

Conclusion

Kelly-Ann S Schlegel's innovative work and dedication to her field have led to significant advancements in medical treatments. Her contributions continue to impact the lives of many, showcasing the importance of innovation in healthcare.